UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 279

Sortiert nach

Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care

Annals of oncology, 2021-10, Vol.32 (10), p.1206-1208

2021

Link zum Volltext

Verfügbarkeit prüfen

Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer

Cancer treatment reviews, 2023-09, Vol.119, p.102597-102597, Article 102597

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimizing the potential of antibody-drug conjugates in oncology

Annals of oncology, 2023-11, Vol.34 (11), p.964-967

2023

Link zum Volltext

Verfügbarkeit prüfen

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Annals of oncology, 2019-11, Vol.30 (11), p.1784-1795

2019

Link zum Volltext

Verfügbarkeit prüfen

Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?

ESMO open, 2023-10, Vol.8 (5), p.101832-101832, Article 101832

2023

Link zum Volltext

Verfügbarkeit prüfen

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

European journal of cancer (1990), 2018-05, Vol.95, p.30-37

2018

Link zum Volltext

Verfügbarkeit prüfen

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

European journal of cancer (1990), 2018-05, Vol.95, p.93-101

2018

Link zum Volltext

Verfügbarkeit prüfen

Defining research priorities without biases: what is the optimal process?

Annals of oncology, 2017-02, Vol.28 (2), p.195-196

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Breast cancer research and treatment, 2018-04, Vol.168 (2), p.357-364

2018

Link zum Volltext

Verfügbarkeit prüfen

Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?

ESMO open, 2024-02, Vol.9 (2), p.102228-102228, Article 102228

2024

Link zum Volltext

Verfügbarkeit prüfen

Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study

Cancer investigation, 2022-07, Vol.40 (6), p.483-493

2022

Link zum Volltext

Verfügbarkeit prüfen

Feasibility study of using an app-based mHealth group challenge to improve physical activity (PA) and fatigue after breast cancer (BC)

Annals of oncology, 2019-05, Vol.30, p.iii71-iii71

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of tamoxifen (TAM) serum concentration on side effects among premenopausal patients (pts) with early breast cancer (BC) in the prospective multicenter CANTO cohort

Annals of oncology, 2019-05, Vol.30, p.iii29-iii29

2019

Link zum Volltext

Verfügbarkeit prüfen

Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs)

Annals of oncology, 2018-10, Vol.29, p.viii94-viii94

2018

Link zum Volltext

Verfügbarkeit prüfen

Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program

Annals of oncology, 2018-10, Vol.29, p.viii710-viii710

2018

Link zum Volltext

Verfügbarkeit prüfen

Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort

Annals of oncology, 2018-10, Vol.29, p.viii704-viii704

2018

Link zum Volltext

Verfügbarkeit prüfen

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort

ESMO open, 2024-05, Vol.9 (5), p.103447-103447, Article 103447

2024

Link zum Volltext

Verfügbarkeit prüfen

Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes

ESMO open, 2024-02, Vol.9 (2), p.102236-102236, Article 102236

2024

Link zum Volltext

Verfügbarkeit prüfen

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

ESMO open, 2022-10, Vol.7 (5), p.100571-100571, Article 100571

2022

Link zum Volltext

Verfügbarkeit prüfen

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)

ESMO open, 2021-08, Vol.6 (4), p.100220-100220, Article 100220

2021

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with enrolment in clinical trials among women with early-stage breast cancer

ESMO open, 2022-06, Vol.7 (3), p.100513-100513, Article 100513

2022

Link zum Volltext

Verfügbarkeit prüfen

Use Of 5-Azacitidine for Therapy-Related Myeloid Neoplasms In Patients With Concomitant Active Neoplastic Disease

Leukemia research, 2017-04, Vol.55, p.58-64

2017

Link zum Volltext

Verfügbarkeit prüfen

P211 Phase 2 neoadjuvant trial: myocet (M), cyclophosphamide (C) +/− trastuzumab (T) and paclitaxel (P) +/− T

Breast (Edinburgh), 2015-03, Vol.24, p.S98-S98

2015

Link zum Volltext

Verfügbarkeit prüfen

“The only thing I know is that I know nothing”: 5-fluorouracil in human milk

Annals of oncology, 2012-02, Vol.23 (2), p.543-544

2012

Link zum Volltext

Verfügbarkeit prüfen

O-195 Disease-free survival is not impacted by fertility preservation techniques for breast cancer women

Human reproduction (Oxford), 2022-06, Vol.37 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 279

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(266)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care

Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer

Optimizing the potential of antibody-drug conjugates in oncology

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients

Defining research priorities without biases: what is the optimal process?

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?

Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study

Feasibility study of using an app-based mHealth group challenge to improve physical activity (PA) and fatigue after breast cancer (BC)

Impact of tamoxifen (TAM) serum concentration on side effects among premenopausal patients (pts) with early breast cancer (BC) in the prospective multicenter CANTO cohort

Applicability of the lung immune prognostic index (LIPI) to metastatic triple negative breast cancer (mTNBC) patients treated with immune checkpoint targeted monoclonal antibodies (ICT mAbs)

Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program

Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort

Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)

Factors associated with enrolment in clinical trials among women with early-stage breast cancer

Use Of 5-Azacitidine for Therapy-Related Myeloid Neoplasms In Patients With Concomitant Active Neoplastic Disease

P211 Phase 2 neoadjuvant trial: myocet (M), cyclophosphamide (C) +/− trastuzumab (T) and paclitaxel (P) +/− T

“The only thing I know is that I know nothing”: 5-fluorouracil in human milk

O-195 Disease-free survival is not impacted by fertility preservation techniques for breast cancer women

Suchergebnisse filtern